Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
PSTI [NASD]
Pluristem Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.35 Insider Own0.60% Shs Outstand57.51M Perf Week-3.79%
Market Cap160.46M Forward P/E- EPS next Y-0.52 Insider Trans15.38% Shs Float51.21M Perf Month-8.52%
Income-16.80M PEG- EPS next Q-0.10 Inst Own1.10% Short Float2.25% Perf Quarter-12.54%
Sales0.70M P/S229.23 EPS this Y2.90% Inst Trans-3.21% Short Ratio6.47 Perf Half Y-27.15%
Book/sh1.20 P/B2.32 EPS next Y-44.40% ROA-26.40% Target Price4.38 Perf Year17.72%
Cash/sh1.12 P/C2.49 EPS next 5Y- ROE-31.00% 52W Range2.26 - 5.00 Perf YTD-12.54%
Dividend- P/FCF- EPS past 5Y43.40% ROI-39.80% 52W High-44.40% Beta-0.24
Dividend %- Quick Ratio10.90 Sales past 5Y- Gross Margin- 52W Low23.01% ATR0.11
Employees87 Current Ratio10.90 Sales Q/Q0.00% Oper. Margin- RSI (14)38.79 Volatility2.27% 3.46%
OptionableYes Debt/Eq0.00 EPS Q/Q-60.00% Profit Margin- Rel Volume1.07 Prev Close2.79
ShortableYes LT Debt/Eq0.00 EarningsNov 20 Payout- Avg Volume177.92K Price2.78
Recom2.20 SMA20-7.23% SMA50-7.76% SMA200-17.77% Volume27,705 Change-0.36%
04-Jun-13Downgrade Maxim Group Buy → Hold
31-May-13Initiated MLV & Co Buy $4.50
25-Jul-12Initiated Maxim Group Buy $8
24-Jul-12Downgrade WBB Securities Speculative Buy → Hold $4 → $3.75
22-May-12Initiated Needham Buy $5
09-Dec-11Initiated Global Hunter Securities Speculative Buy $5
17-Jun-11Initiated Dawson James Buy $5
17-May-11Initiated Oppenheimer Outperform $5
01-Mar-11Initiated WBB Securities Speculative Buy $4
10-Jan-11Initiated National Securities Buy
19-Jun-13 09:04AM  InPlay: Pluristem Therapeutics provides update on clinical status of IC Trials; co has already provided the FDA with additional information and aggregate safety analyses based on the database compiled by the c0 from its previous clinical st Briefing.com
09:00AM  Pluristem Provides Update on Clinical Status of IC Trials GlobeNewswire
10-Jun-13 03:00AM  Pluristem to Deliver Two Presentations During Israel's Largest Biotech Conference: IATI-BioMed GlobeNewswire
06-Jun-13 10:23AM  Pluristem CEO, Zami Aberman Answers the Tough Questions Marketwired
10:23AM  Pluristem CEO, Zami Aberman Answers the Tough Questions Marketwire
05-Jun-13 04:55PM  Setback for Pluristem Therapeutics Zacks +5.59%
04-Jun-13 04:18PM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Pluristem Therapeutics, Inc. PR Newswire -14.37%
09:47AM  Pluristem says FDA puts muscle pain drug study on clinical hold at Reuters
09:02AM  InPlay: Pluristem to receive clinical-hold notice from the U.S. FDA Briefing.com
09:00AM  Pluristem to Receive Clinical-hold Notice From the U.S. FDA GlobeNewswire
06:02AM  Pluristem Therapeutics downgraded by Maxim Group Briefing.com
03:58AM  PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Other Events EDGAR Online
31-May-13 12:44AM  Coverage initiated on Pluristem Therapeutics by MLV & Co Briefing.com
29-May-13 04:00AM  Pluristem to Present at FDA Symposium GlobeNewswire
22-May-13 08:17AM  InPlay: Pluristem Therapeutics announced that Katherina Reiche & Hans-Dieter Volk met; new opportunities discussed to strengthen collaborative relationships using pluristem's placental expanded cells Briefing.com
08:03AM  PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
05:30AM  Pluristem Welcomes Parliamentary State Secretary of the German Federal Ministry for Environmental, Nature Conservation and Nuclear Safety and the Chairman of the Charite Berlin-Brandenburg Center for Regenerative Therapies GlobeNewswire
20-May-13 11:38AM  A Focus On Stem-Cell Therapy And Regenerative Medicine For 2013 at Seeking Alpha
19-May-13 11:52AM  Cloning: A Stem Cell Revolution? at Motley Fool
14-May-13 01:04PM  PLURISTEM THERAPEUTICS INC Financials EDGAR Online Financials
13-May-13 06:10PM  3 Healthcare Stock Stories For Monday Investment Wellness at Wall St. Cheat Sheet
06:23AM  Pluristem Therapeutics' PLX cells may be effective in treating preeclampsia at theflyonthewall.com
04:11AM  InPlay: Pluristem Therapeutics provides preclinical research showing PLX Cells may be effective in treating preeclampsia Briefing.com
03:30AM  Preclinical Research Shows PLX Cells May be Effective in Treating Preeclampsia GlobeNewswire
08-May-13 09:45AM  PLURISTEM THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
07:12AM  Pluristem Therapeutics announces Phase 1 trial to study PLX-PAD cells at theflyonthewall.com
07:01AM  Pluristem Carving Out Distinct Niche in Orthopedic Medicine With New Clinical Trials in Rotator Cuff Repair Marketwired
07:01AM  Pluristem Carving Out Distinct Niche in Orthopedic Medicine With New Clinical Trials in Rotator Cuff Repair Marketwire
07-May-13 03:00AM  Pluristem Develops PLX-RAD Cells for Use in Hematology GlobeNewswire
02-May-13 05:26PM  U.S. judge gives onetime 'King of Biotech' four years in prison at Reuters
30-Apr-13 04:19AM  United Therapeutics' Second PAH Stumble Emphasizes The Need For Pluristem's Therapy at Seeking Alpha
03:00AM  Pluristem to Present at Needham Healthcare and Oppenheimer Israeli Investment Conferences in May 2013 GlobeNewswire
29-Apr-13 05:45AM  Pluristem's PLX-PAD Cells' safety in human lung models shown by research study at theflyonthewall.com
03:00AM  Third Party Research Study Demonstrates Pluristem's PLX-PAD Cells' Safety in Human Lung Models of Pulmonary Hypertension GlobeNewswire
19-Apr-13 08:07PM  3 Healthcare Stock Stories For Weekend Investment Wellness at Wall St. Cheat Sheet
03:30PM  PSTI Plans to Start Phase I Study Zacks
18-Apr-13 03:00AM  Pluristem Expands PLX Product Portfolio in Orthopedics and Sports Medicine GlobeNewswire
17-Apr-13 08:24AM  PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Other Events EDGAR Online
15-Apr-13 11:00AM  UTHR to Move PAH Drug into Phase I Zacks
12-Apr-13 01:45PM  4 Healthcare Stock Stories for Weekend Investment Wellness at Wall St. Cheat Sheet
11-Apr-13 03:19AM  InPlay: Pluristem Therapeutics: United Therapeutics receives regulatory approval to commence Phase I study of Pluristem's PLX-PAD cells for pulmonary arterial hypertension Briefing.com
03:00AM  United Therapeutics Receives Regulatory Approval to Commence Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary Arterial Hypertension GlobeNewswire
10-Apr-13 04:00AM  The Vatican / NeoStem Partnership Looks To Create Interest And Advance Cell Therapy at Seeking Alpha
02:00AM  Pluristem Announces Scientific and Investment Conferences for April 2013 GlobeNewswire
28-Mar-13 09:14AM  Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy at Seeking Alpha
20-Mar-13 03:55AM  InPlay: Pluristem Therapeutics reports on the progress of its Phase I/II clinical trial for the treatment of muscle injury Briefing.com
03:26AM  Phase II Trials Will Be Pivotal For These Stem Cell Companies at Seeking Alpha
03:00AM  Pluristem Reports on the Progress of Its Phase I/II Clinical Trial for the Treatment of Muscle Injury GlobeNewswire
19-Mar-13 09:32AM  PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Other Events EDGAR Online
18-Mar-13 04:40PM  After-Hours Buzz: EA, BAC, DFS & More at CNBC
04-Mar-13 04:53PM  Pluristem & UTHR Progress with PLX-PAD Zacks
28-Feb-13 02:15PM  2012 Stem Cell Standouts And The Outlook For 2013 at Seeking Alpha
27-Feb-13 05:25AM  New Orphan Drug Designation For Pluristem Could Gain Access To FDA 'Progressive Approval' at Seeking Alpha
26-Feb-13 09:11AM  Pluristem Therapeutics moves toward Phase I study of PLX-PAD Cells for PAH at theflyonthewall.com
09:00AM  United Therapeutics Moves Forward Towards a Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary Arterial Hypertension GlobeNewswire
25-Feb-13 11:46AM  Pluristem Therapeutics, Inc. Announces Its Sr. VP of Corporate Development Will Be Presenting at the Accredited Members Spring Micro Cap Investor Conference in Las Vegas Marketwire
21-Feb-13 08:59PM  Pluristem Gets FDA's Orphan Drug Nod for Anemia Treatment at Motley Fool
11:15AM  PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Other Events EDGAR Online
08:01AM  4 Biotech Stocks Under $10 Moving Higher at TheStreet
04:12AM  InPlay: Pluristem Therapeutics receives FDA Orphan Drug status designation for treatment of aplastic anemia Briefing.com
02:30AM  Pluristem Receives FDA Orphan Drug Status Designation for Treatment of Aplastic Anemia GlobeNewswire
15-Feb-13 08:20AM  U.S. Food and Drug Administration Approved 30% More Drugs in 2012 Than the Year Previous Marketwire
13-Feb-13 07:56AM  CORRECTING AND REPLACING -- Pluristem CEO to Participate in Key Roundtable Discussion at the 8th Annual New York Stem Cell Summit '13 GlobeNewswire
03:00AM  Pluristem CEO to Participate in Key Roundtable Discussion at the 8th Annual New York Stem Cell Summit '13 GlobeNewswire
06-Feb-13 01:04PM  PLURISTEM THERAPEUTICS INC Financials EDGAR Online Financials
31-Jan-13 04:51PM  PLURISTEM THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
04:38PM  Pluristem Moves to New Facility Zacks
30-Jan-13 03:00AM  Pluristem Takes Possession of and Moving Into New State-of-the-Art Manufacturing Facility GlobeNewswire
22-Jan-13 09:33AM  3 Regenerative Medicine Companies That Could Deliver In 2013 at Seeking Alpha
08:00AM  Pluristem Updates Cell Manufacturing Industry on Its Proprietary 3D Cell Expansion Technology at Industry Conference GlobeNewswire
07:25AM  Athersys: Short Term Catalyst With Long Term Potential Marketwire
18-Jan-13 07:01AM  Rumors, News and Biotech Buzz Present Various Trade Opportunities Marketwire
16-Jan-13 10:18AM  Why Pluristem Therapeutics Is Poised to Plunge at Motley Fool
08:20AM  Mergers and Acquisitions Within the Biotech Industry Expected to Rise in 2013 Marketwire
15-Jan-13 02:03PM  PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Other Events EDGAR Online +6.79%
01:42PM  InPlay from Briefing.com Briefing.com
01:03PM  InPlay from Briefing.com Briefing.com
12:15PM  InPlay from Briefing.com Briefing.com
11:54AM  InPlay from Briefing.com Briefing.com
11:17AM  InPlay from Briefing.com Briefing.com
10:40AM  InPlay from Briefing.com Briefing.com
10:03AM  InPlay from Briefing.com Briefing.com
09:21AM  InPlay from Briefing.com Briefing.com
08:53AM  InPlay from Briefing.com Briefing.com
08:13AM  InPlay from Briefing.com Briefing.com
07:43AM  InPlay from Briefing.com Briefing.com
07:08AM  InPlay from Briefing.com Briefing.com
06:32AM  InPlay from Briefing.com Briefing.com
05:56AM  InPlay from Briefing.com Briefing.com
05:20AM  InPlay from Briefing.com Briefing.com
04:32AM  InPlay from Briefing.com Briefing.com
04:30AM  InPlay: Pluristem Therapeutics receives approval to expand its Phase II clinical trial in intermittent claudication to Germany Briefing.com
04:00AM  Pluristem Receives Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Germany GlobeNewswire
07-Jan-13 04:06PM  PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
07:00AM  Pluristem's CEO Letter to Shareholders GlobeNewswire
04-Jan-13 06:26PM  Pluristem Progresses with New Facility Zacks
02-Jan-13 04:37PM  Stem Cells, Dr. Oz And A Potentially Lucrative Investment Opportunity at Seeking Alpha +6.58%
29-Dec-12 10:34AM  3 Horrendous Health-Care Stocks This Week at Motley Fool
27-Dec-12 03:00AM  Pluristem Initiates Final Validation of New Manufacturing Facility GlobeNewswire -6.38%
26-Dec-12 05:28PM  PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E EDGAR Online
Pluristem Therapeutics Inc., a bio-therapeutics company, engages in the research, development, and commercialization of standardized cell therapy products and related technologies for the treatment of life threatening diseases. The company's products are derived from human placenta that is a non-controversial, non-embryonic, and adult cell source. Its Placental adherent stromal cells are grown in the company's proprietary PluriX three-dimensional process that allows cells to grow in a natural environment. The company develops placenta expanded cells (PLX) and peripheral artery disease cells, an allogeneic therapeutic product that is in Phase-II clinical trials for the treatment of intermittent claudication, critical limb ischemia, and Buerger's disease. Its PLX product is developed for the treatment of muscle injury, bone marrow diseases, inflammatory bowel disease, and multiple sclerosis, as well as for pulmonary disorders, acute radiation syndrome, acute myocardial infarction, diabetic diastolic heart failure, neuropathic pain, inflammatory bowel disease, multiple sclerosis, and ischemic stroke for which the product is in various pre-clinical trials. Pluristem Therapeutics Inc. is also involved in the development and commercialization of a PLX cell-based product for the treatment of pulmonary arterial hypertension through its license agreement with the United Therapeutics Corporation. The company was formerly known as Pluristem Life Systems Inc. and changed its name to Pluristem Therapeutics Inc. in November 2007. Pluristem Therapeutics Inc. was founded in 2001 and is headquartered in Haifa, Israel.